We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
REVLIMID (Celgene Pty Ltd)
Product name
REVLIMID
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
162 working days (255)
Active ingredients
lenalidomide
Registration type
EOI
Indication
REVLIMID is now also indicated for the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.